News
Hosted on MSN3mon
New malaria vaccine shows high protection in clinical trial - MSNA total of 25 participants were enrolled in the trial, with 10 assigned to the GA2 group, 10 to the GA1 group, and five to the placebo group. Each group consisted of both male and female volunteers.
These GA1 and GA2 ICEs are rapidly transferring between Bacteroidales species in the human gut throughout the world. However, scientists have yet to observe the same, lethal potency in GA1 and GA2 ...
In the GA2 and GA1 groups combined, we detected higher titers of antibodies against P. falciparum CSP (PfCSP) in participants on the day before challenge (1.33±0.35 μg per milliliter) than at ...
Stage B was a double-blind, placebo-controlled phase that compared the protective efficacy of GA2 versus GA1 and placebo (bites from uninfected mosquitoes) after completing three immunization ...
To summarize, this trial demonstrated that the late-arresting parasites (GA2) induced stronger protective immunity (89%) against malaria than early-arresting parasites (GA1, 12%). GA2-induced ...
After immunization, the researchers compared the efficacy of GA2 to GA1 and placebo using controlled human malaria infection. Participants in the placebo group were bitten by uninfected mosquitoes.
These GA1 and GA2 ICEs are rapidly transferring between Bacteroidales species in the human gut throughout the world. However, scientists have yet to observe the same, lethal potency in GA1 and GA2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results